Online recruitment campaign for an influenza virus seasonal epidemic and pandemic Phase 1 study
ID: NOI-NIAID-25-2251388Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Advertising Agencies (541810)

PSC

PHOTO/MAP/PRINT/PUBLICATION- OTHER (T099)

Original Source

https://sam.gov/opp/8a40cc3fcc274098b27ebb1dbd9ac209/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through its National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with BuildClinical, LLC for an online recruitment campaign related to a Phase 1 clinical study of a novel influenza vaccine. The primary objective of this procurement is to effectively recruit healthy adult participants for a clinical trial evaluating the safety, tolerability, and immunogenicity of the mosaic hexavalent influenza vaccine VRC-FLUMOS0116-00-VP, with and without an adjuvant, to address the significant public health challenge posed by seasonal and pandemic influenza. This initiative is crucial as influenza continues to result in substantial morbidity and mortality, and the development of a universal vaccine is a priority for public health. Interested parties may submit capability statements via the NIH electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET, with all submissions requiring registration in the eSASS system. For further inquiries, Dana Monroe can be contacted at dana.monroe@nih.gov or by phone at 406-375-9814.

    Point(s) of Contact
    Dana Monroe
    (406) 375-9814
    dana.monroe@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    NIAID Virology Quality Assurance
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a comprehensive quality assurance program for virologic assays related to HIV and other viral pathogens. The objective is to ensure the validity and comparability of laboratory data through proficiency testing panels and real-time assay controls, which are critical for ongoing and future studies on infectious diseases. This program has been operational since 1988 and supports approximately 110 laboratories globally, emphasizing the importance of maintaining high standards in virologic testing. Proposals are expected to be submitted electronically via the NIAID electronic Contract Proposal Submission (eCPS) website, with the solicitation anticipated to be available on or about January 9, 2025. For further inquiries, interested parties can contact Shawnice Williams at shawnice.williams@nih.gov or Ashley Kinderdine at ashley.kinderdine@nih.gov.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant (AMR) bacterial and fungal pathogens, and the creation of Direct Acting Antivirals (DAA) targeting viruses of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases, with an estimated funding of $28.5 million available for awards in fiscal year 2026. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 must be submitted by January 21, 2025. Interested parties can contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    National Institute of Environmental Health Sciences (NIEHS) Assessment of Immunotoxicity – In Vitro and In Vivo Assessment of Immune Function
    Active
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS), part of the Department of Health and Human Services, is seeking proposals for a federal contract focused on the assessment of immunotoxicity through in vitro and in vivo evaluation of immune function. The objective is to provide comprehensive research services to evaluate how selected test agents may modulate immune responses, utilizing both established and innovative methodologies to reduce animal use in toxicology studies. This contract, anticipated to be a cost-plus-fixed-fee type, is expected to be awarded by September 2025, with a base period of one year and nine optional one-year extensions. Interested parties should direct inquiries to Adam Muhsin at adam.muhsin@nih.gov and monitor the Sam.gov website for the solicitation release, which is expected no sooner than 15 days from this notice.
    A--Clinical Research Operations and Management (CROMS)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the Clinical Research Operations and Management Services (CROMS) contract. This procurement aims to enhance the oversight and efficiency of clinical studies by providing essential systems, tools, and expert resources for data management, site monitoring, and regulatory compliance. The contract is crucial for ensuring high-quality research while adhering to strict federal regulations regarding human subjects, data privacy, and security protocols. The performance period is set from September 30, 2025, to September 29, 2026, with options extending through 2030. Interested parties can reach out to Natalie Bruning at natalie.bruning@nih.gov or Tara C. Knox at knoxt@nhlbi.nih.gov for further details.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug products. The objective of this procurement is to secure high-quality formulated drug products to support preclinical, IND-enabling, and clinical studies, ensuring compliance with current Good Manufacturing Practices (cGMP). This initiative is critical for advancing therapeutic development and enhancing the drug development pipeline, which is vital for public health. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can reach out to Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    In Vitro Assessments of Antimicrobial Activity
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity (IVAAA) program through a Multiple Award Indefinite Quantity contract. The primary objective is to provide in vitro testing capabilities to evaluate the therapeutic potential of compounds against over 270 infectious agents, including bacteria, viruses, fungi, and parasites, thereby enhancing public health preparedness and response to infectious diseases. This solicitation is critical for advancing research in the development of vaccines, therapeutics, and diagnostics, with a funding range between $2,500 and $15 million, and proposals are due by March 10, 2025. Interested parties can contact Alexander Beraud at alexander.beraud@nih.gov for further information.
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of assay kits for the Lumipulse instrument, aimed at quantifying specific biomarkers related to Alzheimer's Disease. The acquisition includes a total of 4,410 assays for biomarkers abeta42, abeta40, and pTau 217, which will be utilized in research involving stored samples from the Baltimore Longitudinal Study of Aging (BLSA) to assess cognitive decline and neurodegeneration. This procurement is critical for advancing Alzheimer’s research and will be awarded as a firm fixed-price purchase order, with quotations due by 5:00 p.m. Eastern Time on January 8, 2025. Interested vendors should contact Iris Merscher at iris.merscher@nih.gov for further details.
    A--National Gene Vector Biorepository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the National Gene Vector Biorepository (NGVB) to support gene therapy research for the National Heart, Lung, and Blood Institute (NHLBI). The contract aims to provide essential resources and services, including administrative management, core laboratory activities, and compliance with FDA regulations and Good Laboratory Practices (GLP). This initiative is crucial for advancing gene therapy capabilities and ensuring the proper archiving of biological specimens and development of assays. Proposals must be submitted by January 10, 2025, and should include detailed technical and business plans, with specific formatting guidelines and a budget submission required. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to enhance public health preparedness against various threats, including infectious diseases and chemical agents. The initiative invites submissions across multiple Areas of Interest (AOIs), including but not limited to vaccine innovations, diagnostic technologies, and therapeutic solutions for acute radiation syndrome and chemical threats. This opportunity is critical for advancing biomedical research and developing effective responses to health emergencies, with multiple awards anticipated based on scientific merit and funding availability. Interested parties must register on SAM.gov and submit their abstracts by specified deadlines, with key submission dates ranging from March 15, 2024, to May 31, 2024, depending on the AOI. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.